, Volume 17, Issue 4, pp 281–286 | Cite as

Interferon-α (IFNα) Daily Dose Versus IFNα Plus Ribavirin for Treatment-Naive Chronic Hepatitis C Patients Infected by Genotype 1b

  • Gaetano Scotto
  • Fausto Campanozzi
  • Antonio D’Adduzio
  • Maria Grimaldi
  • Vincenzina Fazio
Original Research Article



Infection with hepatitis C virus genotype 1b (HCV1b) is known to be a predictive factor of poor response to both interferon-α (IFNα) alone and IFNα plus ribavirin combination therapy.

Study design, patients and methods

This randomised study evaluated the efficacy and safety of daily IFNα administration versus the combination of IFNα plus ribavirin in treatment-naive patients infected with chronic HCV1b. Sixty-two patients were randomised to receive either human leucocyte IFNα 6MU three times weekly for 12 months plus ribavirin 15 mg/kg/day for the first 6 months (group A: 29 patients), or human leucocyte IFNα 3MU daily for 12 months (group B: 33 patients). Response was evaluated by monitoring serum alanine aminotransferase (ALT) and HCV-RNA levels during treatment and follow-up (12 months).

Results and conclusion

Both treatment schedules were relatively well tolerated. Normal ALT levels and negative serum HCV-RNA were observed in 16 of 29 patients (55%) of group A and in 18 of 33 patients (54.5%) of group B at the end of treatment, as well as in 10 of 29 patients (34.5%) of group A and in 12 of 33 patients (36%) of group B at the end of the follow-up. There was no significant difference between the response rates obtained with the two regimens. In naive patients with chronic HCV1b infection, the efficacy of daily administration with IFNα is similar to that of IFNα plus ribavirin administered three times a week.


Sustained Virological Response Sustained Virological Response Rate Fibrosis Score High Initial Dose Sustained Response Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this manuscript. The author appreciates the kind support of Dr M. Grimaldi from Alfa Wassermann S.p.A., in the planning of the study and in the execution of the relevant statistical analysis.


  1. 1.
    Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter, randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321: 1501–6PubMedCrossRefGoogle Scholar
  2. 2.
    Di Bisceglie AM, Martin P, Kassuabudes C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506–10CrossRefGoogle Scholar
  3. 3.
    Di Bisceglie AM. Interferon therapy for chronic viral hepatitis. N Engl J Med 1994; 330: 137–8PubMedCrossRefGoogle Scholar
  4. 4.
    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485–92PubMedCrossRefGoogle Scholar
  5. 5.
    Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon-alfa 2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C: International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493–9PubMedCrossRefGoogle Scholar
  6. 6.
    Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus: International Hepatitis Interventional Therapy Group. Lancet 1998; 352: 1426–32PubMedCrossRefGoogle Scholar
  7. 7.
    Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 342: 1666–72CrossRefGoogle Scholar
  8. 8.
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65PubMedCrossRefGoogle Scholar
  9. 9.
    Lam NP, Neumann AU, Gretch DR, et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alpha. Hepatology 1997; 26: 226–31PubMedCrossRefGoogle Scholar
  10. 10.
    Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alpha-therapy. Science 1998; 282: 103–7PubMedCrossRefGoogle Scholar
  11. 11.
    Bekkering FC, Brouwer JT, Leroux-Roels G, et al. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol 1998; 28: 960–4PubMedCrossRefGoogle Scholar
  12. 12.
    Gross JB, Brandhagen DJ, Gossard AA, et al. Daily interferon to suppress HCV viremia among interferon non-responders [abstract]. Hepatology 1998; 28: 573ACrossRefGoogle Scholar
  13. 13.
    Bruno R, Brunetti E, Maffezzini E, et al. Daily dose interferon regimen for chronic hepatitis C: a prospective randomized study [abstract]. Hepatology 1998; 28: 572ACrossRefGoogle Scholar
  14. 14.
    Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431–5PubMedCrossRefGoogle Scholar
  15. 15.
    Ishak KG. Chronic hepatitis: morphology and nomenclature. Mod Pathol 1994; 7: 690–713PubMedGoogle Scholar
  16. 16.
    Hadziyannis AS, Papaioannou C, Spanou F, et al. Long term efficacy of induction IFN therapy for 4 weeks followed by a standard tiw schedule in chronic hepatitis C [abstract]. Hepatology 1998; 28: 861AGoogle Scholar
  17. 17.
    Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26Suppl. 1: 112S–21SPubMedCrossRefGoogle Scholar
  18. 18.
    Lindsay KL, Davis GL, Schiff ER, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatology 1996; 24: 1034–40PubMedGoogle Scholar
  19. 19.
    Toccaceli F, Rosati S, Scuderi M, et al. Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment. Hepatogastroenterology 1998; 45: 1748–52PubMedGoogle Scholar
  20. 20.
    Cagnoni C, Pancotti D, Carrara G. Management of patients with HCV infection poorly tolerant to recombinant interferon alpha. Hepatogastroenterology 2000; 47: 199–203PubMedGoogle Scholar
  21. 21.
    Cacopardo B, Benanti F, Brancati G, et al. Leukocyte interferon-alpha retreatment for chronic hepatitis C patients previously intolerant to other interferons. J Viral Hepat 1998; 5: 333–9PubMedCrossRefGoogle Scholar
  22. 22.
    Malaguarnera M, Di Fazio I, Restuccia S, et al. Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. Neuropsychobiology 1998; 37: 93–7PubMedCrossRefGoogle Scholar
  23. 23.
    Colombatto P, Oliveri F, Leandro G, et al. Platelet and white blood cell counts during therapy with different types of alpha interferon in patients with chronic viral hepatitis: Investigators of the Alpha Interferon Study Group of Piemonte, Italy. Ital J Gastroenterol Hepatol 1997; 29: 441–7PubMedGoogle Scholar
  24. 24.
    Chemello L, Cavalletto L, Bernardinello E, et al. Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C: TVVH Study Group. J Viral Hepat 1999; 6: 321–7PubMedCrossRefGoogle Scholar
  25. 25.
    Proceedings of the European Association for the Study of the Liver International Consensus Conference on Hepatitis C: Paris, France, 26–27 Feb 1999. J Hepatol 1999; 31 Suppl. 1: 1-268Google Scholar
  26. 26.
    The Australian Hepatitis C Study Group. Efficacy and tolerance of a 6-month treatment course of daily interferon-⇔a for chronic hepatitis C with cirrhosis. J Viral Hepat 1997; 4: 317–23CrossRefGoogle Scholar
  27. 27.
    Zeuzem S, Schimdt JM, Lee JH, et al. Effect of interferon-alpha on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23: 366–71PubMedGoogle Scholar
  28. 28.
    Pol S, Nalpas B, Bourlière M, et al. Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C. Hepatology 2000; 31: 1338–44PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Gaetano Scotto
    • 1
  • Fausto Campanozzi
    • 2
  • Antonio D’Adduzio
    • 3
  • Maria Grimaldi
    • 4
  • Vincenzina Fazio
    • 5
  1. 1.Department of Infectious DiseasesHepatology UnitFoggiaItaly
  2. 2.SERTTorremaggioreItaly
  3. 3.SERTLuceraItaly
  4. 4.Medical DepartmentBolognaItaly
  5. 5.II Laboratory, Infectious DiseasesFoggiaItaly

Personalised recommendations